NewsThursday, 30. August 2012
PARI in clinical trials:
The lungs of non-CF bronchiectasis bronchiectasis
Bronchiectasis is an abnormal widening of one or more airways. Extra mucus is made in the abnormal airways which is prone to infection. patients are often colonized with bacteria such as Pseudomonas aeruginosa and have to be treated with antibiotics. Bronchiectasis Bronchiectasis
Bronchiectasis is an abnormal widening of one or more airways. Extra mucus is made in the abnormal airways which is prone to infection. is a localized, irreversible dilation of part of the bronchial tree caused by destruction of the muscle and elastic tissue, which do not occur as a results of cystic fibrosis cystic fibrosis
Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions. [CF].
A group of scientists from Australia together with the company Aradigm have successfully treated 42 non-CF bronchiectasis bronchiectasis
Bronchiectasis is an abnormal widening of one or more airways. Extra mucus is made in the abnormal airways which is prone to infection. patients with nebulized new-formulation Ciprofloxacin (under development) in a multicenter, randomized, double blind and placebo-controlled study. The dosage was delivered once a day for 24 weeks (3 treatment cycles each consisting of 28 with and 28 days without the antibiotic) via a PARI LC SPRINT nebulizer. The study authors from Australia, New Zealand and the USA reported the following advantages of this therapy:
- Rapidly developed and simultaneously prolonged duration of action thanks to the novel formulation
- Good tolerability
- Highly significant reduction of the pathogen density in expectoration after only 28 days.
- More than double stable phase of the disease (134 vs. 58 days) through the inhalation of new-formulation Ciprofloxacin with PARI LC SPRINT nebulizer.
Fig.: Inhalation of Ciprofloxacin with PARI LC SPRINT prolongs the stable phase of the disease from 58 to 134 days (p < 0.05).
Aradigm is going to continue their scientific project with new-formulation Ciprofloxacin (ARD-3150 – Pulmaquin™) due to the promising results and therefore plans to start the phase-III-study in Royal Brompton Hospital in London.
Source: Serisier DJ et al. 2011, ERS conference, oral presentation 1928